Data from Pharmawand - Curated by EPG Health - Date added 14 August 2019
Eli Lilly announced Taltz (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase IV IXORA-R study, which evaluated the efficacy and safety of Taltz versus Tremfya (guselkumab) in people living with moderate to severe plaque psoriasis (PsO). The IXORA-R trial is the first completed head-to-head (H2H) trial between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as the primary endpoint. At 12 weeks, Taltz met the primary endpoint by demonstrating superiority in the proportion of patients achieving complete skin clearance compared to Tremfya as measured by PASI 100.
In addition, Taltz met all major secondary endpoints up to week 12, which include superiority over Tremfya in the proportion of patients achieving PASI 75 at Week 2, PASI 90 at Weeks 4 and 8, PASI 100 at Weeks 4 and 8, static Physician's Global Assessment (sPGA) 0 at Week 12 and PASI 50 at Week 1. Lilly plans to share results on the remaining key secondary endpoint of proportion of patients achieving PASI 100 at 24 weeks in 2020. In IXORA-R, the safety profile of Taltz was consistent with previously reported results. No new safety signals were detected. Lilly plans to submit detailed data from the IXORA-R study for disclosure at scientific meetings and in peer-reviewed journals.
Comment: The ECLIPSE study has driven a shift to the IL-23 mechanism and away from IL-17 blockers in psoriasis. Results from the head-to-head ECLIPSE psoriasis study recently changed the prescribing habits of almost a third to half of dermatologists in the US and EU, respectively, shifting the favor towards anti-IL-23 Tremfya - over the more established anti-IL-17, Cosentyx.